Anugel(™) Surgical Dressings proven to delivery large benefits in patient comfort following haemorrhoid surgery

Anugel(™) is a new type of surgical dressing that was tested against existing haemostatic gelatinous sponge dressings in a randomised clinical trial on 110 patients. The trial found that Anugel(™) cuts the need for analgesics following surgery to remove Class 3 and 4 haemorrhoids, by 33% and reduces pain as measured on the VAS scale by 60%. Anugel(™) delivers a huge improvement in patient comfort. Details of the trial is being submitted for publication in major journals.

Trial of a promising treatment alleviating arthritis

Our investigators observed that the African food supplement we are investigating for sickle cell treatment, is used traditionally by those with arthritis. This use was discounted initially, as our focus was on sickle cell disease. However, when chemical analysis identified the active compounds in the African Bitter Root plant involved, one group was recognised as having potential for use with arthritis. A sponsored Phase 1 trial was conducted in 2025 with patients having from mild osteoarthritis to severe rheumatoid arthritis, with spectacular results in both groups. An independent Phase 2 double blind trial is scheduled for 2026 in humans, and a separate trial for its use with dogs.
If you are a GP or a Consultant in a UK hospital, and wish your centre to participate, contact us for an information pack, and contact with the independent Principal Investigator for this trial.

Trial of a promising Sickle Cell treatment

Deep Life have run a successful human trial of a sickle cell treatment. Patients in the initial human trial report it provided immediate relief of acute symptoms, and prevented sickling episodes from progressing. No side effects were reported, other than constipation at very high doses. Medical professionals monitoring the trial, report that the treatment is the most effective and promising they have ever come across.

The treatment is the root bark of single African plant used traditionally as a food supplement, combined with a buffer: it is not an opioid or analgesic but is thought to relieve the symptoms by allowing cells to slide over each other more easily.

In addition to volunteers using the treatment to arrest acute sickle cell episodes, patients were traced who had used this extract in the form of a traditional remedy over a 15 year period, and were clinically examined: none had any disability, none had experienced acute episodes since starting taking the treatment though each reported that they had many severe episodes previously. All of the long term patients who were traced retained a functional spleen (oldest patient 41 years old), though with splenomegaly. All were leading a normal life.

In preparation for Phase 3 trials planned to start in 2025, 80 acres of land has been acquired to grow the plant.
If you are a GP or a Consultant in a European hospital, and wish your centre to participate, contact us for an information pack, and contact with the independent Principal Investigator for this trial.

Deep Life Medical has other clinical trials ongoing. These will be reported when complete and analysed in line with PRISMA guidelines.